Cancer News and Research

Latest Cancer News and Research

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

Over one-third of people with terminal cancer do not receive entitled benefits: Study

Over one-third of people with terminal cancer are not getting the benefits to which they are entitled, a study by Macmillan Cancer Support has found.

22 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

SeeChange Health launches first health insurance company in California

SeeChange Health today launched the first new value-based health insurance company in California, offering personalized, value-based health plans that provide incentives to encourage individuals to play an active role in their health management and improve their quality of life. As the first value-based health insurance company to launch in the United States, SeeChange Health brings affordable, next-generation insurance designs to the employer group market.

22 Mar 2010

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

OSI Pharmaceuticals, Inc. will fully redeem on April 21, 2010 all of its remaining outstanding 3.25% Convertible Senior Subordinated Notes due 2023 pursuant to the terms of the indenture under which the Notes were issued in September 2003. The aggregate principal amount currently outstanding of the Notes is $60,467,000. The CUSIP number for these Notes is 671040 AD 5.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BioDelivery Sciences International, Inc. announced the positive outcome of a meeting with the FDA on the development program for BEMA Granisetron, the company’s potential treatment for the prevention of nausea and vomiting associated with cancer therapy. FDA concurred with BDSI’s plans to pursue a development program based on clinical pharmacokinetic data for a 505(b)(2) New Drug Application.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

BSD Medical files 510(k) submission for premarket clearance of Phase II MTX-180

BSD Medical Corporation today announced that the Company has filed a 510(k) submission with the U.S. Food and Drug Administration for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System for ablation of soft tissue.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

Theraclone Sciences, Inc., announced that Zenyaku Kogyo Co. Ltd., has exercised its option for an exclusive license in the Japan territory to Theraclone’s influenza monoclonal antibody program. The collaboration utilizes Theraclone’s I-STAR™ technology to discover broadly protective monoclonal antibodies for the treatment of pandemic influenza and severe seasonal influenza.

22 Mar 2010

Investment report on Gentium from InvestorSoup.com

InvestorSoup.com announces an investment report featuring Gentium SpA. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

22 Mar 2010

AngioDynamics welcomes book on “Irreversible Electroporation”

AngioDynamics today welcomed the publication of the book “Irreversible Electroporation,” published by Springer Berlin Heidelberg.

22 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.

22 Mar 2010

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Vical Incorporated announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influenza (swine flu).

22 Mar 2010

FDA's new rule prohibits sale of cigarettes to children

The U.S. Food and Drug Administration issued a final rule containing a broad set of federal requirements designed to significantly curb access to and the appeal of cigarettes and smokeless tobacco products to children and adolescents in the United States. Published March 19, 2010, the new rule becomes effective June 22, 2010, and has the force and effect of law.

22 Mar 2010

Gene implicated in JSRDs: UCD research team publishes new information

Researchers in University College Dublin (UCD) led by Conway Fellow, Dr Oliver Blacque have revealed new information about a gene implicated in Joubert syndrome and related cerebellar disorders (JSRDs) that are characterised by blindness, bone abnormalities, cystic kidneys, developmental delay and loss of muscle tone and control. The findings from this research, which is funded by Science Foundation Ireland, have been published today in a leading science journal, Journal of Cell Biology.

22 Mar 2010

Lab on a Chip for research on oxygen impact on brain cells

A mini-laboratory that makes it possible, among other things, to study how brain cells in stroke patients are affected by lack of oxygen is being developed by a research team at Luleå University of Technology in Sweden. Lab on a Chip is what the scientists are calling their mini-lab, which is expected to facilitate studies of all sorts of biological cells and how they are affected by different medicines, chemical substances, etc.

22 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

Over one-third of people with terminal cancer do not receive entitled benefits: Study

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

SeeChange Health launches first health insurance company in California

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

BEMA Granisetron development program: BDSI announces positive meeting with FDA

ChemoCentryx undertakes Phase II clinical trial of CCX140

BSD Medical files 510(k) submission for premarket clearance of Phase II MTX-180

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

Investment report on Gentium from InvestorSoup.com

AngioDynamics welcomes book on “Irreversible Electroporation”

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

FDA's new rule prohibits sale of cigarettes to children

Gene implicated in JSRDs: UCD research team publishes new information

Lab on a Chip for research on oxygen impact on brain cells

Cancer radiotherapy can increase risk of cardiovascular disease later in life

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in